Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DR26F3NZR
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $38,788
Award facts
- Contract value 100% obligated
- $38,788.29 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $38,788.29 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on November 13, 2025. This firm fixed-price delivery order, which represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. The award carries no set-aside designation, indicating it was competitively awarded through open competition. Dupixent (dupilumab) is a biologic injectable medication used to treat conditions including moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, reflecting the Department of Defense's need for specialized pharmaceutical support for military and veteran healthcare systems.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, maintains a $999,999,999 prime IDC with DLA Troop Support Medical (contract SPE2DX) extending through December 2026, which serves as the overarching vehicle for this delivery order. The company's extensive federal contract portfolio demonstrates its capacity to supply a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains to support military healthcare programs globally. With an ultimate completion date of November 14, 2025, this delivery order represents a routine pharmaceutical procurement under DLA's established medical supply chain operations.
Quick answers
Who was awarded contract SPE2DR26F3NZR?
SPE2DR26F3NZR was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on November 13, 2025.
How much is contract SPE2DR26F3NZR worth?
The government has obligated $38,788 on SPE2DR26F3NZR.
Is contract SPE2DR26F3NZR an order under another contract?
Yes. SPE2DR26F3NZR is a delivery order under SPE2DR25D2104, an indefinite delivery contract.
Was contract SPE2DR26F3NZR competed?
The extent of competition for SPE2DR26F3NZR was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award